Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients
Abstract Background Studies have shown that some single nucleotide polymorphisms (SNPs) could serve as excellent markers in foretelling the treatment outcome of interferon (IFN) in myeloproliferative neoplasms (MPN). However, most work originated from western countries, and data from different ethni...
Main Authors: | Chih‐Cheng Chen, Ming‐Chung Kuo, Ying‐Hsuan Wang, Sung‐Nan Pei, Ming‐Lih Huang, Chiu‐Chen Chen, Cih‐En Huang, Yi‐Yang Chen, Lee‐Yung Shih |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.7166 |
Similar Items
-
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01) -
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
by: Albert Qin, et al.
Published: (2023-01-01) -
A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
by: Su-Yeon Bang, et al.
Published: (2023-03-01) -
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
by: Aaron T Gerds, et al.
Published: (2023-08-01) -
Aetiology of Myeloproliferative Neoplasms
by: Mary Frances McMullin, et al.
Published: (2020-07-01)